Predictive value of preoperative serum CCL2, CCL18, and VEGF for the patients with gastric cancer

BMC Clinical Pathology

Volumn 13, Issue 1, 2013, Pages

  Wu, Jianghong ^a,b   Liu, Xiaowen ^a,b   Wang, Yanong ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Biological markers; Diagnosis; Gastric cancer

Indexed keywords

CHEMOKINE; CHEMOKINE LIGAND 18; MONOCYTE CHEMOTACTIC PROTEIN 1; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADULT; ARTICLE; BLOOD; CANCER GROWTH; CANCER PATIENT; CANCER STAGING; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PREOPERATIVE PERIOD; STOMACH CANCER;

EID: 84878007554     PISSN: None     EISSN: 14726890     Source Type: Journal    
DOI: 10.1186/1472-6890-13-15     Document Type: Article

References (19)

1. Stomach cancer. Shibata A, Parsonnet J, Cancer epidemiology and prevention New York: Oxford University Press, Schottenfeld D, Fraumeni JF, 3 2006 707 720
2. Global cancer statistics, 2002. Parkin DM, Bray F, Ferlay J, Pisani P, CA Cancer J Clin 2005 55 74 108 10.3322/canjclin.55.2.74 15761078
3. Chemokines in tumor angiogenesis and metastasis. Singh S, Sadanandam A, Singh PK, Cancer Metastasis Rev 2007 26 453 467 10.1007/s10555-007-9068-9 17828470
4. Human monocyte chemoattractant protein-1 (MCP-1). Leonard EJ, Yoshimura T, Immunol Today 1990 11 97 101 2186747
5. Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Salcedo R, Ponce ML, Young HA, Wasserman K, Ward JM, Kleinman HK, Oppenheim JJ, Murphy WJ, Blood 2000 96 34 40 10891427
6. Significant correlation of monocyte chemoattractant protein-1 expression with neovascularisation and progression of breast carcinoma. Saji H, Koike M, Yamori T, Saji S, Seiki M, Matsushima K, Toi M, Cancer 2001 92 1085 1091 10.1002/1097-0142(20010901)92:5<1085::AID-CNCR1424>3.0.CO;2-K 11571719
7. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF, Science 1983 219 983 985 10.1126/science.6823562 6823562
8. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N, Nature 1993 362 841 844 10.1038/362841a0 7683111
9. The biology of VEGF and its receptors. Ferrara N, Gerber HP, LeCouter J, Nat Med 2003 9 669 676 10.1038/nm0603-669 12778165
10. Higher plasma vascular endothelial growth factor levels correlate with menopause, overexpression of p53, and recurrence of breast cancer. Nishimura R, Nagao K, Miyayama H, Matsuda M, Baba K, Yamashita H, Fukuda M, Breast Cancer 2003 10 120 128 10.1007/BF02967636 12736564
11. Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma. De Vita F, Orditura M, Lieto E, Infusino S, Morgillo F, Martinelli E, Castellano P, Romano C, Ciardiello F, Catalano G, Pignatelli C, Galizia G, Cancer 2004 100 270 278 10.1002/cncr.11911 14716760
12. Evaluation of monocyte chemotactic protein-1 levels in peripheral blood of infertile women with endometriosis. Gmyrek GB, Sozanski R, Jerzak M, Chrobak A, Wickiewicz D, Skupnik A, Sieradzka U, Fortuna W, Gabrys M, Chelmonska-Soyta A, Eur J Obstet Gynecol Reprod Biol 2005 122 199 205 10.1016/j.ejogrb.2005.03. 019 15893866
13. Monocyte chemoattractant protein-1 serum levels in ovarian cancer patients. Hefler L, Tempfer C, Heinze G, Mayerhofer K, Breitenecker G, Leodolter S, Reinthaller A, Kainz C, Br J Cancer 1999 81 855 859 10.1038/sj.bjc.6690776 10555758
14. Correlations between serum monocyte chemotactic protein-1 levels, clinical prognostic factors, and HER-2/neu vaccine-related immunity in breast cancer patients. Dehqanzada ZA, Storrer CE, Hueman MT, Foley RJ, Harris KA, Jama YH, Kao TC, Shriver CD, Ponniah S, Peoples GE, Clin Cancer Res 2006 12 2 478 486 10.1158/1078-0432.CCR-05-1425 16428490
15. Profile of monocyte chemoattractant protein-1 circulating levels in gastric cancer patients. Tonouchi H, Miki C, Tanaka K, Kusunoki M, Scand J Gastroenterol 2002 37 830 833 12190098
16. Association of serum vascular endothelial growth factor-C and lymphatic vessel density with lymph node metastasis and prognosis of patients with gastric cancer. Wang TB, Deng MH, Qiu WS, Dong WG, World J Gastroenterol 2007 13 1794 1798 17465468
17. Measurement of circulating levels of VEGF-A, -C, and -D and their receptors, VEGFR-1 and -2 in gastric adenocarcinoma. AI-Moundhri MS, AI-Shukaili A, AI-Nabhani M, AI-Bahrani B, Burney IA, Rizivi A, Ganguly SS, World J Gastroenterol 2008 14 3879 3883 10.3748/wjg.14.3879 18609713
18. Predictive significance of preoperative serum VEGF-C and VEGF-D, independently and combined with CA19-9, for the presence of malignancy and lymph node metastasis in patients with gastric cancer. Tsirlis TD, Kostakis A, Papastratis G, Masselou K, Vlachos I, Papachristodoulou A, Nikiteas NI, J Surg Oncol 2010 102 699 703 10.1002/jso.21677 20672317
19. Clinical utility of circulating matrix metalloproteinase-7 (MMP-7), CC chemokine ligand 18 (CCL18) and CC chemokine ligand 11 (CCL11) as markers for diagnosis of epithelial ovarian cancer. Zohny SF, Fayed ST, Med Oncol 2010 27 4 1246 1253 10.1007/s12032-009-9366-x 19937162